Related references
Note: Only part of the references are listed.FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Frederik L. Giesel et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer
Eric M. Robinson et al.
ANNALS OF THORACIC SURGERY (2020)
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
Wei Mu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Comparison Between F-18-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Giovanni Rossi et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Respiratory Gating and the Performance of PET/CT in Pulmonary Lesions
Cinzia Crivellaro et al.
CURRENT RADIOPHARMACEUTICALS (2020)
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
C. Proto et al.
CANCER TREATMENT REVIEWS (2019)
F-18-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy
Laura Evangelista et al.
NUCLEAR MEDICINE COMMUNICATIONS (2019)
Imaging of Precision Therapy for Lung Cancer: Current State of the Art
Hyesun Park et al.
RADIOLOGY (2019)
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer A Meta-analysis and Individual Patient-Level Analysis
Yunfang Yu et al.
JAMA NETWORK OPEN (2019)
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
Hoda Anwar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Lais Osmani et al.
SEMINARS IN CANCER BIOLOGY (2018)
The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
Christos Sachpekidis et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
Benedikt M. Schaarschmidt et al.
EUROPEAN RADIOLOGY (2017)
Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease
Hossein Jadvar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
Steve Y. Cho et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017
Heber MacMahon et al.
RADIOLOGY (2017)
TNM Staging of Non-Small Cell Lung Cancer: Comparison of PET/MR and PET/CT
Martin W. Huellner et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer
Ken Kodama et al.
ANNALS OF THORACIC SURGERY (2016)
Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT
Sang Min Lee et al.
EUROPEAN RADIOLOGY (2016)
Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer
Tomonari Kinoshita et al.
LUNG CANCER (2016)
Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT
Maria J. Garcia-Velloso et al.
LUNG CANCER (2016)
The Current and Evolving Role of PET in Personalized Management of Lung Cancer
Esther Mena et al.
PET CLINICS (2016)
Recent Trends in the Identification of Incidental Pulmonary Nodules
Michael K. Gould et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Pretreatment FDG-PET Metrics in Stage III Non-Small Cell Lung Cancer: ACRIN 6668/RTOG 0235
Nitin Ohri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immunerelated Adverse Events
Jennifer J. Kwak et al.
RADIOGRAPHICS (2015)
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of 18F-FDG Uptake at PET-Association with Treatment Response and Prognosis
Gary J. R. Cook et al.
RADIOLOGY (2015)
Pretreatment FDG-PET Metrics in Stage III Non-Small Cell Lung Cancer: ACRIN 6668/RTOG 0235
Nitin Ohri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Prognostic Value of Total Lesion Glycolysis by 18F-FDG PET/CT in Surgically Resected Stage IA Non-Small Cell Lung Cancer
Seong Yong Park et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Diagnostic efficacy of PETand PET/CT for recurrent lung cancer: a meta-analysis
Yan-Qi He et al.
ACTA RADIOLOGICA (2014)
18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer
Matthijs H. van Gool et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non-Small Cell Lung Cancer
Matthijs H. van Gool et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
NF-κB protein expression associates with 18F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism
Viswam S. Nair et al.
LUNG CANCER (2014)
[18F]FDG Positron Emission Tomography within Two Weeks of Starting Erlotinib Therapy Can Predict Response in Non-Small Cell Lung Cancer Patients
Mammar Hachemi et al.
PLOS ONE (2014)
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
Mariam Jamal-Hanjani et al.
PLOS BIOLOGY (2014)
Heterogeneity in [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Non-Small Cell Lung Carcinoma and Its Relationship to Metabolic Parameters and Pathologic Staging
Ober Van Gomez Lopez et al.
MOLECULAR IMAGING (2014)
Prognostic Value of Metabolic Tumor Burden from F-18-FDG PET in Surgical Patients with Non-small-cell Lung Cancer
Hao Zhang et al.
ACADEMIC RADIOLOGY (2013)
Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
Shengri Liao et al.
ACADEMIC RADIOLOGY (2012)
Early [F-18]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
Ryo Takahashi et al.
CLINICAL CANCER RESEARCH (2012)
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system
Shamus R. Carr et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2012)
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?
Fergus Davnall et al.
INSIGHTS INTO IMAGING (2012)
Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
Thomas Zander et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
Deniz Kahraman et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
Matthias R. Benz et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial
Barbara M. Fischer et al.
THORAX (2011)
Diagnostic value of 18F-FDG PET/CT and dedicated bone imaging in childhood sarcoma
Franziska Walter et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell Lung Cancer Update of a Systematic Review and Meta-Analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project
Marianne Paesmans et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
[18F] Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung
Hee-Jung Sohn et al.
CLINICAL CANCER RESEARCH (2008)
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy
Cary Dehing-Oberije et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: A model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography
Christophe Dooms et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Recommendations on the use of F-18-FDG PET in oncology
James W. Fletcher et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer
Noriaki Sunaga et al.
LUNG CANCER (2008)
Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)
Roland T. Ullrich et al.
PLOS ONE (2008)
Solitary pulmonary nodules: Meta-analytic comparison of cross-sectional imaging modalibes for diagnosis of malignancy
Paul Cronin et al.
RADIOLOGY (2008)
Anatomo-metabolic characteristics of atelectasis in F-18FDG-PET/CT imaging
Victor H. Gerbaudo et al.
EUROPEAN JOURNAL OF RADIOLOGY (2007)
Metabolic tumor burden predicts for disease progression and death in lung cancer
Percy Lee et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer
Susanne Martina Eschmann et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma
Takashi Ohtsuka et al.
CANCER (2006)
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer
CJ Hoekstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
MP Mac Manus et al.
LUNG CANCER (2005)
The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival
RJ Cerfolio et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2005)
Early FDG-pet imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation
RJ Hicks et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer - A meta-analysis
MK Gould et al.
ANNALS OF INTERNAL MEDICINE (2003)
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography
D Lardinois et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy
MP Mac Manus et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions - A meta-analysis
MK Gould et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
